Fox Chase Case Study Demonstrates NGS Panel's Ability to Accurately Diagnose Cancer | GenomeWeb http://t.co/cC3aXcwcqw
5:35am August 21st 2015 via Hootsuite
Rare Genomics Institute Announces Winners of Rare Disease Challenge | GenomeWeb http://t.co/JaS0W4Fdgv
4:55am August 21st 2015 via Hootsuite
Analysis suggests that increased research investment hasn't lead to improved health outcomes | GenomeWeb http://t.co/qopobNSPNr
10:50pm August 20th 2015 via Hootsuite
NIH Aims to Fund Cancer Informatics Research Projects | GenomeWeb http://t.co/mjkTNZXXVo
9:50pm August 20th 2015 via Hootsuite
RT @ArthurCaplan: How many clinical trials are feasible for a rare disease with a small patient population? http://t.co/dQpYH5Ty74 via @WSJ
8:35pm August 20th 2015 via Hootsuite
B Budlowe in Madrid http://t.co/ddwCYqZS2l MT @genomeatlantic:Genomics: The Integral Tool of Today's Forensic Science http://t.co/RrPdBAqHS0
7:30pm August 20th 2015 via Hootsuite
RT @DailyNewsGW: New Zealand 'Virus Hunter' Team Explores MinION for Influenza Genome, Metagenomic Sequencing http://t.co/dpxBBaL3Qe
6:25pm August 20th 2015 via Hootsuite
MT @lpachter: Cool fig from @atifbd.graduate thesis. Radii prop. to log read length; borders to error rate. http://t.co/0tqQgVholh
5:25pm August 20th 2015 via Hootsuite
RT @rahman_nazneen: Who’s the First Person in History Whose Name We Know? Fascinating. http://t.co/C2ozOhYMVF
4:12pm August 20th 2015 via Hootsuite
RT @Sander1Arts: How Are You Perceived? Your Audience Decides Within 30 Seconds via @forbes http://t.co/8V14ILUj8g
2:20pm August 20th 2015 via Hootsuite
Hi Twitter followers: I'm done for today. Thanks for listening and for coming up to introduce yourselves IRL! Until next time - Dale #NGDx15
12:34pm August 20th 2015 via Hootsuite
Sninsky:AlloMap is 11gene test, gene expression score. CARGO, IMAGE, CARGOII, eIMAGE, OAR studies from 2004 #NGDx15
12:32pm August 20th 2015 via Hootsuite
Sninsky: Six replicates with Horizon, linearity 1-4%, up to 12%. Also 0.2, 0.4% #NGDx15
Sninsky: Used also plasma mixtures, method based material with 8398 (GIAB), and standardized analysis (DNAnexus and precisionFDA) #NGDx15
12:31pm August 20th 2015 via Hootsuite
Sninsky: Reference materials via Horizon - for mixed cell lines mimic the trace individual. Will shear size, mimic cfDNA, dPCR char #NGDx15
12:30pm August 20th 2015 via Hootsuite
Sninsky:Mentions this paper, others http://t.co/j3yBTHug0A CareDx depends on SNPs, no need for donor/recipient genotypes #NGDx15
12:28pm August 20th 2015 via Hootsuite
Sninsky: #NG Mentions NIPT (5-20% fetal cfDNA); cancer (0.01-10% complext interpretation); solid organ (0.1-15% dd-cfDNA) Dx15
12:25pm August 20th 2015 via Hootsuite
Sninsky: Diagnostic kit dev - analytic validation, clinical validation, clin utility, comparative effectiveness. #NGDx15
12:24pm August 20th 2015 via Hootsuite
Sninsky: Long-term care - median survival is 10-12y for heart/kidney. 23% cancer, 12% infection, 6% renal failure, 18% graft failure #NGDx15
12:22pm August 20th 2015 via Hootsuite
Sninsky: Impact chart - 2.5K heart procedures/y, 25K total patient pools. 16.9k kidney, of 180K total #NGDx15
12:21pm August 20th 2015 via Hootsuite
John Sninsky (CareDx CA) "Clinical translation of cfDNA for solid organ transplantation" #NGDx15
12:20pm August 20th 2015 via Hootsuite
Diaz: Mentions the interplay between CTC research, exosomes, microRNAs, and other biomarkers with ctDNA. 'A resurgence' #NGDx15
12:17pm August 20th 2015 via Hootsuite
CEO of CareDx made a comment that they spent $150M for AlloMap over 10y for a $20M return (unclear if that was total or per-year) #NGDx15
12:06pm August 20th 2015 via Hootsuite
Q:Can these studies be done retrospectively? Diaz: A:Biobanks may just give 50uL, not mL's. Also how sample was collected / stored #NGDx15
11:53am August 20th 2015 via Hootsuite
Diaz: Lower costs are needed, felt more competition needed in the NGS equipment arena to lower costs #NGDx15
11:44am August 20th 2015 via Hootsuite
Q:About cost and effort it takes for studies A:Diaz:It is high risk, the reward for Dx isn't there (but is there for drugs) #NGDx15
11:43am August 20th 2015 via Hootsuite
Pantel: Raises the point of competing alternatives - serum markers (cheapa nd reimbursed) and imaging (expensive) #NGDx15
11:41am August 20th 2015 via Hootsuite
Diaz: Cell-free offers great opportunities, not only in cancer but also transplantation. #NGDx15
11:40am August 20th 2015 via Hootsuite
Diaz: Is there a high-value biomarker? ctDNA provides a way to provide that - equally or even more valuable than a drug. #NGDx15
11:38am August 20th 2015 via Hootsuite
Rosenfeld: 'So much of the underlying science is unknown', but still may provide very good patient benefit nonetheless. #NGDx15
11:36am August 20th 2015 via Hootsuite
Rosenfeld: A field moving fast and attracting a great deal of attention. One challenge is focus - what's the 'must have' app? #NGDx15
11:34am August 20th 2015 via Hootsuite
Pantel: Other points - what survival benefit? Also screening - complex but of great interest, cohorts of at-risk individuals #NGDx15
11:30am August 20th 2015 via Hootsuite
Pantel: Starts with the dynamics of dying tumor cells; ctDNA variable and treatment effect; clinical intervention studies #NGDx15
11:29am August 20th 2015 via Hootsuite
Panel participants: Luis Diaz PGDx, Nitzan Rosenfeld Inivata, Klaus Pantel (Huniv Hamburg) #NGDx15
11:28am August 20th 2015 via Hootsuite
Papadopoulos:Q:Levels and %, were total DNA also correlated? A:Stage I and SII, not a lot of variation in total DNA #NGDx15
11:23am August 20th 2015 via Hootsuite
Papadopoulos: Q:Head and Neck seemed that early stage perf. better? A:Not known, could be due to location NGDx15
11:22am August 20th 2015 via Hootsuite
Papadopoulos: A vision for screening. Acknowledged Bert Vogelstein, Ken Kinzler and Luis Diaz. #NGDx15
11:21am August 20th 2015 via Hootsuite
Papadopoulos: Combination - 90-100% sens, 92-98% spec. Could reduce unneeded surgeries by 90%. Combining data for classification #NGDx15
11:19am August 20th 2015 via Hootsuite
Papadopoulos: Mutations in the cyst fluid represent the ones in the neoplasm #NGDx15 Just published, major collab: http://t.co/yVW73CbLMl
11:18am August 20th 2015 via Hootsuite
Papadopoulos:Oppy for early detection. 572K new pancreatic cysts ID'd in the US. Conventional criteria not good to distinguish #NGDx15
11:17am August 20th 2015 via Hootsuite
Papadopoulos: For head and neck, proximity to oral cavity can increase sensitivity. Last - pancreatic cysts #NGDx15
11:16am August 20th 2015 via Hootsuite
Papadopoulos: In Pap smear samples; 100% of endometrial. Head and neck: HPV in saliva, plasma #NGDx15 Reference: http://t.co/52AtxGPiDN
11:15am August 20th 2015 via Hootsuite
Papadopoulos: CNS - get closer to the source #NGDx15 Recent work published here: http://t.co/2HpoOCR7eO
11:13am August 20th 2015 via Hootsuite
Papadopoulos: Localized - 91% stool, 61% ctDNA; Adenomas 75% stool, 10% ctDNA. #NGDx15
11:10am August 20th 2015 via Hootsuite
Papadopoulos: 5mL vs 10mL inc sens. Early detection - other sources could be stool for CRC. 100% for both in advanced #NGDx15
Papadopoulos: How to raise sensitivity? Many choices - methods, collection. Clear correlation bet detection and amt of ctDNA #NGDx15
11:09am August 20th 2015 via Hootsuite
Papadopoulos: ctDNA in localized cancer (CRC, Gasto, panc, br) - proportion of cases range 48% - 73%. #NGDx15
11:08am August 20th 2015 via Hootsuite
Papadopoulos: Preliminary - recurrence rate is clear between types of ctDNA detected for CRC recurrence. #NGDx15
11:07am August 20th 2015 via Hootsuite
Papadopoulos:Unpublished work: ctDNA as a marker for recurrence. ID SII CRC 4-10w post-op plasma. 2y surveill, test panel of genes #NGDx15
11:06am August 20th 2015 via Hootsuite
Papadopoulos: Resistance mutations detected post-treatment, not detected prior. Serve as both 'early warning' and mech of resist #NGDx15
11:05am August 20th 2015 via Hootsuite
